Carlyle to Acquire Baxter's Kidney Care Segment (Vantive) for $3.8B
August 13, 2024
Funds managed by Carlyle, in partnership with Atmas Health, have signed a definitive agreement to acquire Baxter's Kidney Care segment (to be named Vantive) for $3.8 billion. The transaction, expected to close in late 2024 or early 2025 subject to regulatory approvals, will provide Baxter approximately $3.5 billion in cash (net after-tax proceeds estimated at ~$3.0 billion) and creates a standalone kidney care company with more than 23,000 employees and 2023 revenues of $4.5 billion.
- Buyers
- Carlyle, Atmas Health
- Targets
- Vantive
- Sellers
- Baxter International Inc.
- Industry
- Medical Devices
- Location
- Illinois, United States
- Transaction Type
- Divestiture
Explore More
Related Acquisitions
-
Eli Lilly and Company to Acquire Ventyx Biosciences
January 8, 2026
Pharmaceuticals
Eli Lilly and Company has entered into a definitive agreement to acquire Ventyx Biosciences for approximately $1.2 billion. The deal values Ventyx at $14.00 per share in cash and is expected to close in the first half of 2026, subject to shareholder and regulatory approvals.
-
Carlyle and SK Capital Acquire bluebird bio
May 14, 2025
Healthcare Services
bluebird bio entered into a definitive agreement to be acquired by funds managed by Carlyle and SK Capital Partners, with expected close in the first half of 2025. Under the deal, bluebird stockholders are set to receive $3.00 per share in cash plus a contingent value right (CVR) of up to $6.84 per share if a net sales milestone is achieved by 2027 (or an alternative $5.00 per share cash option later added).
-
Bain Capital to Acquire Mitsubishi Tanabe Pharma in $3.3B Carve-Out
February 7, 2025
Pharmaceuticals
Bain Capital has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (Tanabe Pharma) in a carve-out transaction from Mitsubishi Chemical Group Corporation. The deal values Tanabe Pharma at approximately 510 billion JPY (~$3.3 billion) and is expected to close in the third quarter of 2025, subject to regulatory clearance and approvals.
-
CVC Acquires Therakos Business from Mallinckrodt for $925M
August 5, 2024
Medical Devices
CVC Capital Partners Fund IX agreed to acquire the Therakos extracorporeal photopheresis business from Mallinckrodt plc for $925 million in a carve-out transaction. CVC said it will invest in further research, indication expansion and geographic growth of Therakos while key Therakos employees will transition with the business; Mallinckrodt will use proceeds to substantially reduce net debt.
-
KKR-backed Biosynth Carbosynth Acquires vivitide; Ampersand Rolls Over Stake
March 17, 2022
Biotechnology
KKR has invested in Biosynth Carbosynth through its Health Care Strategic Growth Fund II, and Biosynth Carbosynth has acquired vivitide, a global provider of custom peptides and antibody services. Existing owner Ampersand Capital Partners rolled over its entire stake and will be a substantial minority shareholder in the combined global life‑sciences reagents and custom synthesis platform to accelerate geographic expansion, broaden capabilities, and expand the product portfolio.
-
Pharos Capital Acquires Vantage Outsourcing to Build Ophthalmology Services Platform
September 22, 2021
Healthcare Services
Pharos Capital Group has acquired Vantage Outsourcing, a cataract surgical support services provider headquartered in Effingham, Illinois. Pharos will partner with industry executive Bradley Hill and work with Vantage's existing leadership—co-founder and CEO Ann Deters and President Chris Swing (who retain minority stakes)—to build a broader surgical support services platform across ophthalmology and other specialties.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.